Liraglutide Cost in North Dakota 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Does Liraglutide Actually Cost in North Dakota in 2026?

The out-of-pocket cost of liraglutide in North Dakota depends heavily on which version you are prescribed, whether your insurer covers it, and whether you use a savings card or compounding pharmacy. Retail cash prices average roughly $900 per month across North Dakota pharmacies in 2026, compared to a Novo Nordisk manufacturer list price of approximately $1,349 per month for a 5-pen carton of Saxenda.

Retail Cash Price vs. Manufacturer List Price

The gap between list price and cash price exists because pharmacies negotiate acquisition costs and some pass a portion of those savings to uninsured patients. Even so, $900 per month is a significant barrier for most North Dakotans. The 3.0 mg maintenance dose of Saxenda requires one 18 mg/3 mL prefilled pen every six days, making the monthly supply five pens.

Victoza (liraglutide 1.2 mg or 1.8 mg for type 2 diabetes) carries a similar list price structure. Because no FDA-approved generic liraglutide existed as of early 2026, there is no substitutable lower-cost branded alternative at the retail counter. The FDA's drug approval database confirms Saxenda's NDA 206321 and Victoza's NDA 022341 remain held by Novo Nordisk without generic competition. 1

How the SCALE Trial Contextualizes the Price

The SCALE Obesity and Prediabetes trial (N=3,731, published NEJM 2015) showed liraglutide 3.0 mg produced a mean weight loss of 8.4 kg over 56 weeks versus 2.8 kg with placebo (P<0.001). 2 That 5.6 kg difference translates to roughly 5.4% additional body weight reduction, a clinically meaningful outcome that partly justifies the drug's premium pricing. Patients who respond well to liraglutide often maintain that loss for years, so monthly cost must be weighed against long-term cardiometabolic benefit.

The LEADER cardiovascular outcomes trial (N=9,340) also demonstrated that liraglutide 1.8 mg reduced the rate of major adverse cardiovascular events by 13% compared to placebo in adults with type 2 diabetes and high cardiovascular risk (hazard ratio 0.87, 95% CI 0.78 to 0.97, P<0.001 for non-inferiority). 3 That finding influenced guideline bodies to recommend liraglutide specifically for patients with established cardiovascular disease.

Does North Dakota Medicaid Cover Liraglutide?

North Dakota Medicaid does not cover liraglutide for chronic weight management or type 2 diabetes as of 2026. This is one of the largest coverage gaps affecting ND patients who rely on public insurance.

ND Medicaid Formulary Status

The North Dakota Department of Human Services administers Medicaid through a fee-for-service model. GLP-1 receptor agonists used for obesity are excluded from the preferred drug list. Liraglutide prescribed for type 2 diabetes (Victoza) may theoretically qualify for a prior authorization review, but approval rates for branded non-preferred agents remain low without documented failure of metformin plus at least one other preferred oral agent.

The American Diabetes Association 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or at high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended." 4 However, a clinical guideline recommendation does not automatically generate Medicaid coverage. Prescribers appealing a Medicaid denial should cite the LEADER trial data and the patient's cardiovascular risk profile.

Medicare Part D and ND

Medicare Part D plans are prohibited by federal law from covering drugs approved solely for weight loss. Saxenda therefore remains excluded from Part D formularies nationwide, including in North Dakota. Victoza coverage under Part D varies by plan; patients with a diabetes diagnosis should request a formulary exception in writing supported by the LEADER outcome data. 5

State Employee Health Plan

The North Dakota Public Employees Retirement System (NDPERS) health plan does cover some GLP-1 agents under prior authorization for type 2 diabetes. Coverage for the obesity indication (Saxenda) is not standard and requires documented BMI criteria and a prior-authorization request from the prescribing clinician.

Is Compounded Liraglutide Legal in North Dakota?

Yes. Licensed 503A compounding pharmacies in North Dakota may legally prepare liraglutide for individual patients who have a valid prescription from a licensed prescriber. The cost is approximately $150 per month, making it roughly 83% cheaper than the average retail cash price of $900 per month.

What 503A Means for Patients

A 503A pharmacy compounds medications on a patient-specific basis under a prescription. These pharmacies are regulated by the North Dakota Board of Pharmacy and must comply with USP standards for sterile preparations. Compounded liraglutide is not FDA-approved as a finished product, which means it does not carry the same quality-assurance data as commercially manufactured Saxenda.

The FDA has issued guidance clarifying that compounding of a commercially available drug like liraglutide is only appropriate when there is a documented patient-specific need, such as an allergy to an excipient in the commercial product or a documented drug shortage. 6 Prescribers should document the clinical rationale clearly in the patient chart.

503B Outsourcing Facilities

503B outsourcing facilities operate under stricter FDA oversight and may distribute compounded products to healthcare providers without individual prescriptions. As of early 2026, liraglutide is not on the FDA's official drug shortage list, which limits the scope of 503B facilities to compound and distribute it at scale. Patients and prescribers should verify current shortage status directly with the FDA drug shortage database before initiating a compounded liraglutide prescription. 7

Quality and Dosing Considerations

Compounded liraglutide is typically prepared as a multi-dose vial requiring self-administration with insulin-style syringes rather than the prefilled pen device used for Saxenda. The dose titration schedule mirrors the FDA-approved protocol: 0.6 mg daily for one week, then weekly increases of 0.6 mg until reaching the 3.0 mg maintenance dose. 8 Patients should confirm that their compounding pharmacy uses pharmaceutical-grade liraglutide API and can provide a certificate of analysis.

Which Insurance Plans Cover Liraglutide in North Dakota?

Commercial insurance coverage in North Dakota varies widely by employer plan and carrier. No state mandate requires coverage of anti-obesity medications, so most coverage decisions rest with individual plan sponsors.

Commercial Carriers Operating in ND

Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica all offer products in the ND commercial market. Coverage for Saxenda (obesity indication) under these plans typically requires:

• BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity
• Documentation of a three-to-six-month supervised diet and exercise program
• Prior authorization approval renewed annually

The American Association of Clinical Endocrinology (AACE) 2023 obesity guidelines state that "pharmacotherapy is indicated as an adjunct to lifestyle intervention for patients with a BMI of 27 or higher and at least one weight-related comorbidity." 9 That guideline language often appears in commercial plan medical policies as the clinical criteria for prior authorization.

Employer Self-Funded Plans

Many larger North Dakota employers, including state agencies and agricultural cooperatives, self-fund their health benefits. Self-funded plans are not subject to state insurance mandates and set their own formularies. Some have added GLP-1 coverage with strict utilization management; others have removed it entirely due to cost. Employees should contact their HR department or benefits administrator directly to confirm formulary tier and prior authorization requirements.

ACA Marketplace Plans

ACA marketplace plans sold in North Dakota are not required to cover anti-obesity medications. Victoza (diabetes indication) is more frequently covered than Saxenda. Patients on marketplace plans should review the Summary of Benefits and Coverage document for each plan during open enrollment, paying specific attention to the specialty drug tier copay and deductible structure.

How Does the Novo Nordisk Savings Card Work in North Dakota?

Novo Nordisk offers a savings card for commercially insured patients that can reduce out-of-pocket cost to as low as $99 per month for Saxenda or Victoza. The card is not available to patients covered by Medicare, Medicaid, or any other federal or state government program.

Eligibility and Enrollment

Eligible patients enroll at the Novo Nordisk patient savings website or through their prescriber's office. The savings card typically covers the gap between insurance copay and $99, up to a monthly maximum benefit. Annual benefit caps exist, commonly ranging from $1,800 to $3,600 per calendar year depending on the program version active at enrollment.

North Dakota patients who are uninsured do not qualify for the commercially insured savings card but may apply for the Novo Nordisk Patient Assistance Program, which provides medication at no cost to qualifying low-income patients. Income thresholds are generally set at or below 400% of the federal poverty level. 10

GoodRx and Third-Party Discount Cards

GoodRx coupons for liraglutide in North Dakota can bring retail pharmacy prices down by 20 to 40% in some zip codes. Results vary by pharmacy chain. Bismarck and Fargo tend to have the most competitive GoodRx prices due to pharmacy density. Third-party discount cards cannot be combined with insurance or manufacturer savings cards. Patients should compare both options at the point of purchase.

Can You Get Liraglutide Via Telehealth in North Dakota?

Yes. Telehealth prescribing of liraglutide is legally permitted in North Dakota. A licensed prescriber must conduct an appropriate evaluation, which may occur via synchronous video visit, before issuing a controlled-substance-free prescription for liraglutide. Liraglutide is not a controlled substance under federal or North Dakota state law, making telehealth prescribing administratively straightforward.

North Dakota Telehealth Prescribing Rules

North Dakota Century Code Chapter 43-17 governs medical practice, including telehealth. Prescribers using telehealth platforms must establish a valid provider-patient relationship before prescribing. An audio-only or asynchronous questionnaire alone does not satisfy the standard for a new patient. Video evaluation that includes a review of current medications, metabolic labs, and cardiovascular history meets the standard for most carriers and licensing boards. 11

What HealthRX Telehealth Patients in ND Receive

HealthRX prescribers serving North Dakota patients complete a structured intake that includes a 12-point cardiometabolic screening checklist, review of fasting glucose or HbA1c within the past 12 months, and a documented weight history going back at least 12 months. Prescriptions are sent electronically to a pharmacy of the patient's choice, including licensed 503A compounding pharmacies that offer the lower-cost compounded formulation.

What Is the Cheapest Way to Get Liraglutide in North Dakota?

For most uninsured or underinsured North Dakota patients, compounded liraglutide through a licensed 503A pharmacy offers the lowest monthly cost at approximately $150 per month, compared to $900 per month cash price at retail and $1,349 list price.

Cost Comparison by Access Route

The four primary access pathways in North Dakota and their approximate 2026 monthly costs:

| Access Route | Approx. Monthly Cost | |---|---| | Manufacturer list price (no savings) | $1,349 | | Retail cash price (ND average) | $900 | | Commercial insurance (post-copay, with savings card) | $99, $250 | | Licensed 503A compounded liraglutide | $150 |

Patients with commercial insurance that covers Saxenda and who qualify for the Novo Nordisk savings card pay the least. For patients without qualifying insurance, licensed 503A compounding is the most affordable lawful option.

Step Therapy and Prior Authorization Strategy

Many North Dakota commercial plans require documented failure of orlistat or phentermine/topiramate before approving a GLP-1 agent for obesity. Prescribers should complete prior authorization paperwork with:

• Current BMI measurement dated within 90 days
• Documentation of a supervised diet and exercise program of at least 12 weeks
• Any qualifying comorbidities (hypertension, dyslipidemia, sleep apnea, prediabetes)
• Reference to the SCALE Obesity trial data showing 8.4 kg mean weight loss at 56 weeks 2
• Reference to AACE 2023 obesity pharmacotherapy criteria 9

A well-documented prior authorization request citing named trials and guideline-endorsed BMI thresholds substantially improves first-pass approval rates. The Endocrine Society's clinical practice guideline on obesity pharmacotherapy also supports GLP-1 receptor agonist use in patients with BMI 30 or higher, or BMI 27 or higher with comorbidity. 12

Liraglutide Dosing Reference for North Dakota Prescribers

Prescribers issuing liraglutide prescriptions in North Dakota should follow the FDA-approved titration schedule regardless of whether the patient uses a commercial or compounded product.

FDA-Approved Titration Schedule (Saxenda/Obesity)

• Week 1: 0.6 mg once daily subcutaneous
• Week 2: 1.2 mg once daily subcutaneous
• Week 3: 1.8 mg once daily subcutaneous
• Week 4: 2.4 mg once daily subcutaneous
• Week 5 onward: 3.0 mg once daily subcutaneous (maintenance)

If a patient does not tolerate dose escalation, the prescriber may hold at the current dose for an additional week before advancing. The FDA label states that patients who do not achieve at least 4% weight loss from baseline after 16 weeks at 3.0 mg should discontinue, as continued response is unlikely. 8

Contraindications to Screen Before Prescribing

The FDA label lists personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2 (MEN2) as absolute contraindications. The Endocrine Society recommends against prescribing any GLP-1 receptor agonist to patients with these histories. 12 Prescreening questionnaires used in telehealth settings should include direct questions about thyroid cancer history.

Pancreatitis history requires a shared-decision discussion. The LEADER trial investigators did not find a statistically significant increase in acute pancreatitis events with liraglutide 1.8 mg vs. Placebo (0.4% vs. 0.3%, P<0.05 threshold not met), though the label still carries a precaution. 3

Are There State or Federal Assistance Programs for ND Liraglutide Patients?

State-level pharmaceutical assistance programs in North Dakota are limited. The North Dakota Prescription Connection program connects uninsured or underinsured residents with manufacturer patient assistance programs. Patients with incomes at or below 200% of the federal poverty level may qualify for Novo Nordisk's Patient Assistance Program at no cost. 13

The Health Resources and Services Administration (HRSA) 340B drug pricing program allows federally qualified health centers (FQHCs) to purchase Saxenda at a significantly reduced acquisition cost and pass those savings to eligible low-income patients. North Dakota FQHCs include facilities operated by the United Tribes Technical College health programs and several rural health clinics. Patients who receive primary care at an FQHC should ask their provider whether 340B pricing applies to their liraglutide prescription. 14

The Affordable Care Act's essential health benefits framework does not classify obesity pharmacotherapy as an essential benefit, so marketplace plan coverage remains optional for insurers. The U.S. Preventive Services Task Force recommends intensive behavioral counseling for adults with obesity (B recommendation), which some plans use as a basis to cover anti-obesity counseling while still excluding medications. 15